# Kailera Therapeutics (KLRA) — News

KLRA · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/klra/news

## Recent headlines

- [Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra sells 34.2 mln shares in Korra Holding for EGP 205.3 mln - EGX](https://www.ainvest.com/news/mohamed-aiman-kamal-el-din-mohamed-abdul-khaliq-korra-sells-34-2-mln-shares-korra-holding-egp-205-3-mln-egx-2610) — AInvest Wire, Oct 13, 2026
  Mohamed Aiman Kamal El Din Mohamed Abdul Khaliq Korra has sold 34.2 million shares in Korra Holding (KORA) for a total value of EGP 205.3 million, according to recent data from the Egyptian Exchange . The transaction reflects significant activity in the stock, which has seen a recent decline in…
- [Kailera Therapeutics - Topline data from Kainetic phase 3 trials expected in mid-2028](https://www.ainvest.com/news/kailera-therapeutics-topline-data-kainetic-phase-3-trials-expected-mid-2028-2609) — AInvest Wire, Sep 30, 2026
- [Novo says Hengrui obesity pill to enter phase 1 tests soon](https://www.ainvest.com/news/novo-hengrui-obesity-pill-enter-phase-1-tests-2609) — AInvest Wire, Sep 30, 2026
  Kailera Therapeutics, in collaboration with Chinese pharmaceutical firm Hengrui Medicine, has announced the initiation of phase 1 trials for a novel triple-receptor obesity compound targeting GLP-1, GIP, and glucagon receptors. This development positions the drug as a potential competitor in the…
- [Jiangsu Hengrui Pharmaceuticals says unit's ribupatide injection marketing application accepted by China's drug regulator](https://www.ainvest.com/news/jiangsu-hengrui-pharmaceuticals-unit-ribupatide-injection-marketing-application-accepted-china-drug-regulator-2609) — AInvest Wire, Sep 9, 2026
  Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for ribupatide injection for the treatment of type 2 diabetes. This follows the successful completion of a Phase 3 clinical trial…
- [Shares of Kailera Therapeutics up 1% after weight-loss drug meets main goal of late-stage trials in China](https://www.ainvest.com/news/shares-kailera-therapeutics-1-weight-loss-drug-meets-main-goal-late-stage-trials-china-2607) — AInvest Wire, Jul 7, 2026
  Shares of Kailera Therapeutics (Nasdaq: KLRA) rose 1% following the announcement that its weight-loss drug, HRS-9531 (KAI-9531), met its primary endpoints in a late-stage clinical trial conducted in China. The Phase 3 GEMINI-1 trial, led by partner Hengrui Pharma, demonstrated significant weight…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).